Merck & Co., Inc. (MRK) Q3 2023 Earnings Call Transcript

Merck & Co., Inc. (NYSE:MRK) Q3 2023 Earnings Conference Call October 26, 2023 9:00 AM ET

Company Participants

Peter Dannenbaum - Vice President, Investor Relations
Rob Davis - Chairman and CEO
Caroline Litchfield - Chief Financial Officer
Dr. Dean Li - President, Merck Research Labs

Conference Call Participants

Chris Shibutani - Goldman Sachs
Mara Goldstein - Mizuho
Carter Gould - Barclays
Seamus Fernandez - Guggenheim
Terence Flynn - Morgan Stanley
Andrew Baum - Citi
Louise Chen - Cantor
Chris Schott - JPMorgan
Geoff Meacham - Bank of America
Steve Scala - TD Cowen
Evan Seigerman - BMO Capital Markets
Mohit Bansal - Wells Fargo

Operator

[Started Abruptly]

… Merck & Co. Q3 Sales and Earnings Conference Call. At this time, all participants are in a listen-only mode until the question-and-answer session of today’s conference. [Operator Instructions]

This call is being recorded. If you have any objections, you may disconnect at this time. I will now turn the call over to Mr. Peter Dannenbaum, Vice President, Investor Relations. Sir, you may begin.

Peter Dannenbaum

Thank you, Julie, and good morning, everyone. Welcome to Merck’s third quarter 2023 conference call. Speaking on today’s call will be Rob Davis, Chairman and Chief Executive Officer; Caroline Litchfield, Chief Financial Officer; and Dr. Dean Li, President of Merck Research Labs.

Before we get started, I’d like to point out a few items. You will see that we have items in our GAAP results, such as acquisition related charges, restructuring costs and certain other items. You should note that we have excluded these from our non-GAAP results and provide a reconciliation in our press release.

I would like to remind you that some of the statements that we make today may be considered forward-looking statements within the meaning of the Safe-Harbor provision of the U.S. Private Securities